89 related articles for article (PubMed ID: 19320648)
1. The value of the oral glucose tolerance test, random serum growth hormone and mean growth hormone levels in assessing the postoperative outcome of patients with acromegaly.
Karavitaki N; Fernandez A; Fazal-Sanderson V; Wass JA
Clin Endocrinol (Oxf); 2009 Dec; 71(6):840-5. PubMed ID: 19320648
[TBL] [Abstract][Full Text] [Related]
2. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
Colao A; Pivonello R; Cavallo LM; Gaccione M; Auriemma RS; Esposito F; Cappabianca P; Lombardi G
Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
[TBL] [Abstract][Full Text] [Related]
3. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
[TBL] [Abstract][Full Text] [Related]
4. Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly.
Kim EH; Oh MC; Lee EJ; Kim SH
Neurosurgery; 2012 May; 70(5):1106-13; discussion 1113. PubMed ID: 22067418
[TBL] [Abstract][Full Text] [Related]
5. Measurement of basal growth hormone (GH) is a useful test of disease activity in treated acromegalic patients.
Jayasena CN; Wujanto C; Donaldson M; Todd JF; Meeran K
Clin Endocrinol (Oxf); 2008 Jan; 68(1):36-41. PubMed ID: 18088288
[TBL] [Abstract][Full Text] [Related]
6. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels.
Freda PU; Nuruzzaman AT; Reyes CM; Sundeen RE; Post KD
J Clin Endocrinol Metab; 2004 Feb; 89(2):495-500. PubMed ID: 14764751
[TBL] [Abstract][Full Text] [Related]
7. Use of the oral glucose tolerance test to define remission in acromegaly.
Vierhapper H; Heinze G; Gessl A; Exner M; Bieglmayr C
Metabolism; 2003 Feb; 52(2):181-5. PubMed ID: 12601629
[TBL] [Abstract][Full Text] [Related]
8. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly.
Sherlock M; Aragon Alonso A; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
Clin Endocrinol (Oxf); 2009 Jul; 71(1):74-81. PubMed ID: 19178529
[TBL] [Abstract][Full Text] [Related]
9. Value of early postoperative random growth hormone levels and nadir growth hormone levels after oral glucose tolerance testing in acromegaly.
Rotermund R; Burkhardt T; Rohani Z; Jung R; Aberle J; Flitsch J
Growth Horm IGF Res; 2018 Aug; 41():64-70. PubMed ID: 29555234
[TBL] [Abstract][Full Text] [Related]
10. Comparison of oral glucose tolerance test (OGTT) 100 g with OGTT 75 g for evaluation of acromegalic patients and the impact of gender on test reproducibility.
Arafat AM; Müller L; Möhlig M; Mayr B; Kremenevskaya N; Pfeiffer AF; Buchfelder M; Schöfl C
Clin Endocrinol (Oxf); 2011 Nov; 75(5):685-91. PubMed ID: 21575028
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
Charalampaki P; Hildebrandt G; Schaeffer HJ; Schönau E; Klug N
Exp Clin Endocrinol Diabetes; 1998; 106(2):130-4. PubMed ID: 9628244
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of suppression of growth hormone levels following a 75g oral glucose tolerance test.
Nazaimoon WM; Ng ML; Satgunasingam N; Khalid BA
Med J Malaysia; 1992 Jun; 47(2):103-9. PubMed ID: 1494329
[TBL] [Abstract][Full Text] [Related]
13. GH and mortality in acromegaly.
Sheppard MC
J Endocrinol Invest; 2005; 28(11 Suppl International):75-7. PubMed ID: 16625851
[TBL] [Abstract][Full Text] [Related]
14. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
Bastemir M; Akin F; Yaylali GF
Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
[TBL] [Abstract][Full Text] [Related]
15. Homocysteine levels in acromegaly patients.
Hekimsoy Z; Ozmen B; Ulusoy S
Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
[TBL] [Abstract][Full Text] [Related]
16. Do "so-called" normal growth hormone concentrations (2-5 micrograms/l) indicate cure in acromegaly?
Levitt NS; Ratanjee BD; Abrahamson MJ
Horm Metab Res; 1995 Apr; 27(4):185-8. PubMed ID: 7750902
[TBL] [Abstract][Full Text] [Related]
17. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
18. Biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients.
Christiansen Arlien-Søborg M; Trolle C; Alvarson E; Bæk A; Dal J; Otto Lunde Jørgensen J
Endocrine; 2017 Jun; 56(3):589-594. PubMed ID: 28260207
[TBL] [Abstract][Full Text] [Related]
19. Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?
Dobri G; Niwattisaiwong S; Bena JF; Gupta M; Kirwan J; Kennedy L; Hamrahian AH
Endocrine; 2019 Apr; 64(1):139-146. PubMed ID: 30415402
[TBL] [Abstract][Full Text] [Related]
20. Bromocriptine reduces growth hormone in acromegaly.
Bell PM; Atkinson AB; Hadden DR; Kennedy L; Leslie H; Merrett JD; Sheridan B
Arch Intern Med; 1986 Jun; 146(6):1145-9. PubMed ID: 3718102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]